1-3 of 3
Gary Schiller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia

Clinical Trials & Observations
Mark Levis, Alexander Perl, Gary Schiller, Amir T. Fathi, Gail Roboz, Eunice S. Wang, Jessica Altman, Trivikram Rajkhowa, Makoto Ando, Takeaki Suzuki, Ruth Ann Subach, Gary Maier, Timothy Madden, Mary Johansen, Kin Cheung, Michael Kurman, Catherine Smith
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2527–2535.
https://doi.org/10.1182/bloodadvances.2023010619
Published: 2024
Includes: Supplemental data
Journal Articles

Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

Clinical Trials & Observations
Abdulraheem Yacoub, Uma Borate, Raajit K. Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O’Connell, Swati Goel, Stephen T. Oh, Gary Schiller, James McCloskey, Jeanne Palmer, Houston Holmes, Steven Hager, Albert Assad, Susan Erickson-Viitanen, Feng Zhou, Naval Daver
Journal: Blood Advances
Blood Adv (2024) 8 (6): 1515–1528.
https://doi.org/10.1182/bloodadvances.2023011620
Published: 2024
Includes: Supplemental data
Journal Articles

Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories

Clinical Trials & Observations
Uma Borate, Fei Yang, Richard Press, Amy S. Ruppert, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Dean C. Pavlick, Luke Juckett, Brianna Norris, Taylor Bucy, Amy Burd, Eytan M. Stein, Prapti Patel, Maria R. Baer, Wendy Stock, Gary Schiller, William Blum, Tibor Kovacsovics, Mark Litzow, James Foran, Nyla A. Heerema, Leonard Rosenberg, Sonja Marcus, Ashley Yocum, Mona Stefanos, Brian Druker, John C. Byrd, Ross L. Levine, Alice Mims
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6048–6054.
https://doi.org/10.1182/bloodadvances.2022009008
Published: 2023
Includes: Supplemental data